Connecticut Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Connecticut Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.18M	Buy	2,653 +5	+0.2%	+$2.33K	0.05%	136
2025 Q4	$1.2M	Hold	2,648	–	–	0.05%	143
2025 Q3	$1.04M	Sell	2,648 -244	-8%	-$102K	0.05%	153
2025 Q2	$1.29M	Sell	2,892 -11	-0.4%	-$5.07K	0.06%	129
2025 Q1	$1.41M	Sell	2,903 -45	-2%	-$21K	0.07%	115
2024 Q4	$1.19M	Buy	2,948 +19	+0.6%	+$8.81K	0.06%	118
2024 Q3	$1.36M	Sell	2,929 -19	-0.6%	-$9.13K	0.07%	127
2024 Q2	$1.38M	Buy	2,948 +14	+0.5%	+$6.08K	0.07%	121
2024 Q1	$1.23M	Buy	2,934 +53	+2%	+$22.4K	0.07%	129
2023 Q4	$1.17M	Buy	+2,881	New	+$1.06M	0.07%	129

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Connecticut Wealth Management's VRTX Position: Q1 2026 in Review

Connecticut Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.19% in Q1 2026, buying an estimated $2.33K and bringing the position to 2,653 shares worth $1.18M. The position accounts for 0.05% of the portfolio, ranked #136.

Connecticut Wealth Management first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.41M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Connecticut Wealth Management held 2,653 shares of Vertex Pharmaceuticals worth $1.18M as of Q1 2026.
Connecticut Wealth Management bought 5 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.33K.
Vertex Pharmaceuticals made up 0.05% of Connecticut Wealth Management's portfolio in Q1 2026, its #136 holding.
Connecticut Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Connecticut Wealth Management's Vertex Pharmaceuticals position peaked at $1.41M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Connecticut Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.